Hansa Biopharma AB (OSTO:HNSA) Float Percentage Of Total Shares Outstanding: 0.00% (As of Jul. 08, 2026)


OSTO:HNSA Hansa Biopharma AB OSTO:HNSA
49 GF Score
Price kr34.80
GF Value kr24.49
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Hansa Biopharma AB Float Percentage Of Total Shares Outstanding?

Hansa Biopharma AB OSTO:HNSA +0.69% 49 Float Percentage Of Total Shares Outstanding is 0.00% as of Jul. 08, 2026. GuruFocus rates OSTO:HNSA with a GF Score™ of 49/100 and a GF Value™ of kr24.49 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Hansa Biopharma AB's float shares is 0.00 Mil. Hansa Biopharma AB's total shares outstanding is 99.73 Mil. Hansa Biopharma AB's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Hansa Biopharma AB's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Hansa Biopharma AB's Institutional Ownership is 20.14%.

OSTO:HNSA
49GF Score
Hansa Biopharma AB OSTO:HNSA
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hansa Biopharma AB Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Hansa Biopharma AB's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/99.73
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 0.00% mean?
Hansa Biopharma AB (OSTO:HNSA) has a Float Percentage Of Total Shares Outstanding of 0.00% as of Jul. 08, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Hansa Biopharma AB and its competitors.
Is Hansa Biopharma AB's Float Percentage Of Total Shares Outstanding too high?
Hansa Biopharma AB's current Float Percentage Of Total Shares Outstanding is 0.00%. Overall, Hansa Biopharma AB has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansa Biopharma AB's Float Percentage Of Total Shares Outstanding compare to VRTX and REGN?
Hansa Biopharma AB's Float Percentage Of Total Shares Outstanding of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Hansa Biopharma AB and its competitors. Hansa Biopharma AB's current Float Percentage Of Total Shares Outstanding is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansa Biopharma AB stock overvalued right now?
Based on GuruFocus' analysis, Hansa Biopharma AB (OSTO:HNSA) is currently considered Significantly Overvalued. The stock's GF Value™ is kr24.49, compared to a current price of kr34.80 — trading 42.1% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 0.00%. Hansa Biopharma AB's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Hansa Biopharma AB (OSTO:HNSA), the current Float Percentage Of Total Shares Outstanding is 0.00% as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hansa Biopharma AB (OSTO:HNSA) Overvalued in 2026?

Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued. The current stock price of kr34.80 is trading 42.1% above its estimated GF Value™ of kr24.49. GuruFocus considers Hansa Biopharma AB to be Significantly Overvalued.

Key valuation signals for OSTO:HNSA:

  • Float Percentage Of Total Shares Outstanding: 0.00%
  • GF Value™: kr24.49 vs. price of kr34.80 (42.1% above fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the OSTO:HNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hansa Biopharma AB Business Description

Address Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
49GF Score

Get the complete analysis for OSTO:HNSA

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr34.80
Price
kr24.49
GF Value